Needle-free Promise Biora Therapeutics is building BioJet, a needle-free, swallowable autoinjector platform aimed at oral dosing of proteins and biologics. This presents a sales opportunity to engage with biologics developers seeking patient-friendly delivery alternatives and to explore partnerships or licensing for oral biologic formulations.

Clinical Momentum Recent Frost Radar recognition and ongoing BioJet platform development indicate a strong R&D trajectory and credibility in smart delivery formulations. Use this to approach prospective customers with collaboration or grant-backed pilot programs and to differentiate with validated innovation.

Targeted GI Delivery The platform focuses on targeted drug delivery to the GI tract, suggesting sales angles with gastroenterology, inflammatory bowel disease, and oral biologic therapies where localized GI delivery can improve efficacy and patient adherence.

Strategic Funding With substantial capital raised and multiple financing rounds totaling hundreds of millions, Biora may seek partners for co-development, manufacturing scale-up, or joint ventures to accelerate clinical milestones and market readiness.

SME Scale Fit As a smaller biotech with 11-50 employees and a tech-forward stack, Biora is likely seeking nimble, cost-effective collaborators and contract development/manufacturing organizations to accelerate manufacturing, regulatory planning, and early-phase trials while managing risk.